Johnson & Johnson (NYSE:JNJ) Trading Down 1.1% - Time to Sell?

Key Points

• Johnson & Johnson's stock price dropped by 1.1%, trading as low as $175.77, with a significant volume decline of 90% compared to its average session.
• Analysts have differing ratings on the stock, with two analysts rating it as Strong Buy, nine as Buy, and nine as Hold, leading to an overall rating of "Moderate Buy" and a consensus target price of $176.29.
• The company reported earnings of $2.77 per share in the last quarter, exceeding estimates and indicating a 5.8% year-over-year revenue increase, alongside an upcoming quarterly dividend of $1.30 per share.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price fell 1.1% during mid-day trading on Tuesday . The stock traded as low as $175.77 and last traded at $176.39. 912,989 shares were traded during mid-day trading, a decline of 90% from the average session volume of 8,979,405 shares. The stock had previously closed at $178.41.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Citigroup upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Finally, Guggenheim reiterated a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Stock Performance

The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $425.06 billion, a PE ratio of 18.87, a P/E/G ratio of 2.28 and a beta of 0.41. The company's fifty day simple moving average is $163.95 and its 200 day simple moving average is $159.48.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Institutional Trading of Johnson & Johnson

Institutional investors have recently added to or reduced their stakes in the business. Semmax Financial Advisors Inc. lifted its stake in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after purchasing an additional 72 shares in the last quarter. GFG Capital LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $35,000. Highline Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the first quarter valued at $47,000. Finally, 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.